Intuitive Surgical stock heads into the open after a 39% slide from its peak

At the close on September 11, 2026, Intuitive Surgical stock traded at USD 369.15 on the Nasdaq, down about 39% from its January 2025 high amid slower procedure growth and rising competition. The shares now head into the open with investors watching upcoming Q3 2026 results.

Intuitive Surgical stock closed at USD 369.15 on the Nasdaq on September 11, 2026, leaving the shares roughly 39% below their January 2025 peak near USD 610 and reflecting a reset in investor expectations after a strong multi-year run. Per recent market data, the move left the stock down markedly from its high even as the company continues to post double-digit revenue growth.

September 11, 2026 in numbers

Intuitive Surgical Inc. (ISIN US46120E6023, Nasdaq: ISRG) finished the September 11, 2026 session at USD 369.15 in Nasdaq trading, compared with a prior high near USD 610 earlier in 2025, a decline of roughly 39% from that peak as noted by Tikr. According to that same analysis, the stock weakness followed a period when U.S. procedure growth slowed and a new soft-tissue rival entered the market, intensifying competitive pressures on Intuitive Surgical’s core robotic surgery franchise.

As Tikr reported, Intuitive Surgical’s second-quarter 2026 revenue reached USD 2,892.30 million with adjusted earnings per share of USD 2.80, both ahead of consensus, and an EBIT margin of about 42.11 percent, underlining that the recent share-price pressure stems less from current financial underperformance than from concerns about future growth and competitive dynamics. In parallel, a report from 36Kr Europe highlighted that second-quarter 2026 revenue rose 19 percent year on year to USD 2.892 billion, with instruments and accessories contributing USD 1.735 billion, systems USD 685 million and services USD 472 million, confirming solid underlying demand despite the share-price correction.

Today’s outlook around upcoming Q3 results

Heading into today’s session on September 14, 2026, the next major catalyst for Intuitive Surgical shares is the company’s third-quarter 2026 earnings report, which market commentary expects to arrive in October and to serve as a key test of whether procedure volumes and system placements can sustain recent growth rates, as noted by Tikr. With second-quarter figures already showing robust revenue and margin performance, investors today are likely to focus on commentary about competitive developments, regulatory trends and hospital capital spending that could shape expectations for that Q3 release.

Broader market and sector moves may also influence Intuitive Surgical stock in today’s trading, as changes in risk appetite for high-growth medical-technology names and shifts in expectations for health-care procedure volumes can affect valuation multiples. In this context, the company’s demonstrated ability to grow revenue near 20 percent and maintain strong free cash flow margins, as underlined by recent analysis from Tikr, remains a central reference point for how the shares may respond to upcoming data and news flow.